BSC statement regarding the use of TNK for treatment of acute ischemic stroke

The Belgian Stroke Council is currently awaiting a decision by FAGG and RIZIV/INAMI regarding marketing and reimbursement of tenecteplase (TNK) for treatment of acute ischemic stroke in Belgium.

Based on the current evidence obtained from randomized, controlled trials comparing TNK with alteplase (tPA), the European Stroke Organisation (ESO) has stated that TNK (dosed at 0.25mg/kg) may be used as an alternative for tPA in eligible patients with acute ischemic stroke. The effectiveness and safety of TNK is comparable to tPA. Acute stroke patients with an occlusion of a large intracranial blood vessel may particularly benefit from TNK.

For more information, we refer to the BSC opinion statement and the ESO guideline on the use of TNK, attached to this post.

BSC opinion statement in dutch

BSC opinion statement in french

ESO guideline on TNK use